Compare Atlassian Corporation PLC (TEAM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs TG Therapeutics Inc — how do they compare? Atlassian Corporation PLC trades at $206.21 (market cap $51.53B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: Atlassian Corporation PLC is far larger — about 6.3× TG Therapeutics Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 64 Days and TG Therapeutics Inc for 16 Days on average.
| TEAM | TGTX | |
|---|---|---|
Market Cap | $51.53B | $8.16B |
Volume | 2,904,511 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $203.57 | $59.06 |
52-Week Low | $57.15 | $26.94 |
Typical Hold Time | 64 Days | 16 Days |
Enterprise Value | $51.52B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $205.09, up 4.81% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though RSI suggests potential overbought conditions. Revenue growth remains robust at $5.22B for 2025, with improving margins despite negative net income. Recent news highlights accelerating cloud migration and AI adoption driving investor optimism.
Outlook remains positive with 69.77% analyst buy ratings and a $140B addressable market growing at 14% annually. Key risks include persistent negative profitability, high valuation multiples, and competitive pressures. The stock trades above consensus price target of $191.16, suggesting near-term consolidation potential despite long-term growth catalysts from AI and cloud expansion.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
